% | $
Quotes you view appear here for quick access.

Ligand Pharmaceuticals Incorporated Message Board

  • able_was_i_ere_i_saw_elba2001 able_was_i_ere_i_saw_elba2001 Nov 29, 2001 6:08 PM Flag

    New company presentation

    available through company website.

    $300M revenue 2004?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thanks for pointing out the new presentation. Ligand never stints on data. I don't think they have a future doing rock videos though.

      I'm afraid the best most of us can ever conclude after going through one of these is that there's a lot of stuff going on. Even Henry would have trouble separating the votes from the chads.

    • Elan has accumulated an impressive portfolio of marketed oncology products and a growing pipeline of R&D projects. This franchise includes:

      * Myocet/D99, a novel liposomal doxorubicin formulation for the treatment
      of metastatic breast cancer which has recently been launched in the EU,
      is under registration in Canada and is in Phase II trials in the US.
      Phase III plans are being finalized.
      * ELL-12, a novel ether lipid which we expect to enter into Phase II
      trials for renal cell carcinoma, metastatic melanoma, non-small cell
      lung cancer and myelodysplastic syndrome.
      * BRT-216, a novel taxane which we expect to enter into Phase I trials
      for solid tumors.
      * Elan is developing a range of oncology products licensed for Europe
      from Ligand Pharmaceuticals. These products are Targretin(TM) capsules
      (marketed) Targretin(TM) gel (in registration) and Onzar/Ontak(TM) (in
      registration), all initially developed for the treatment of cutaneous
      T-cell lyphoma, and Panretin(TM) gel, approved for the treatment of
      Kaposi's sarcoma.
      * Depocyte(TM) (cytarabine liposomal injection) licensed for Europe from
      SkyePharma, which is approved for the treatment of lymphomatous

113.21+1.42(+1.27%)2:52 PMEDT